Lab to Lives – Détails, épisodes et analyse

Two leaders from Sionna Therapeutics walk through a 15‑year journey from Genzyme science to a public company advancing NBD1‑targeted therapies in cystic fibrosis. We examine why most patients still fall short of normal CFTR, how a predictive assay de‑risks choices, and what it takes to finance, hire, and execute with patients as the North Star.

Visit: sionnatx.com

Do you want to try the quiz from this episode? Find the link on our LinkedIn profile: https://www.linkedin.com/company/labtolives/

Would you like to join the show as a guest or collaborator? Find out how on our website: https://www.labtolives.com/

________
Reach out to Ivanna Rosendal

Join the conversation on our LinkedIn page

Visit www.labtolives.com

Hosts

Alexander Booth aka the MedTech Guy

Dimitri Borisevich aka the start-up Guy

Ivanna Rosendal aka the R&D pharma Gal

Lire plusRéduire

AI Won’t Replace Writers, But Writers Who Use AI Will Outpace The Rest with Bilal Bham

mercredi 3 décembre 2025 • Durée 24:12

What if the documents behind a clinical trial were written with the patient’s voice in mind and delivered at the speed modern science deserves? We sit down with writer, consultant, and patient-advocate Bilal Bham to unpack how protocols, clinical trial applications, and clinical study reports actually get made, why structure beats chaos, and where AI genuinely shortens timelines without cutting corners. From first protocol outlines to final submissions, Bilal shares a process that blends proprietary AI with rigorous human review to turn dense source data into clear, regulator-ready narratives.

The conversation gets real about the craft. Bilal argues that new writers still need to learn documents end-to-end: where to find truth in source files, how to build arguments across sections, and how to keep stakeholders aligned from biostats to clinical operations. AI helps when you feed it the right ingredients, starting with comprehensive bullet-pointed outlines rather than instant prose. That discipline shaves weeks off delivery and keeps quality high, especially when regulators are exploring AI on their side of the table and expect traceability, accuracy, and transparent logic.

We also explore the power of inclusion. Living with Graves’ disease and thyroid eye disease, Bilal explains how patient experience sharpens trial design, consent language, and symptom reporting. Diversity is not a banner; it is better science. Recruiting across local communities in the UK, US, and Europe strengthens external validity and reveals gene-environment differences that change safety and efficacy. Pair that with plain-English patient summaries, fair compensation, and trusted community partners, and you get trials that are faster to run, easier to understand, and more likely to help the people who need them most.

If you care about clinical trials, regulatory writing, medical communications, AI in pharma, and building inclusive studies that actually work in the real world, this conversation is for you. Subscribe, share with a colleague, and leave a review with your take: where should inclusion start in clinical research?

Do you want to try the quiz from this episode? Find the link on our LinkedIn profile:

Prevention Pays: How Technology Is Revolutionizing Mental Health with Eva Papadopoulou

Saison 6 · Épisode 8

mercredi 21 mai 2025 • Durée 28:38

Why do we wait until we're severely unwell before seeking help? In this thought-provoking episode, I'm joined by Eva Papadopoulou, a mental health professional and expert in digital and AI-enabled healthcare solutions, to explore the transformative potential of preventative mental healthcare.

Eva reveals the stark reality of our current healthcare systems - less than 10% of budgets are allocated to prevention, despite evidence showing preventative approaches lead to better outcomes and cost savings. Using dental care as a compelling example, she illustrates how cultural shifts can transform how we approach healthcare. "We take care of our mind and body before it breaks, not after," Eva explains, offering a vision where mental wellbeing is nurtured proactively rather than repaired reactively.

We delve into key areas ripe for preventative intervention, including youth mental health (with most conditions developing before age 25) and workplace wellbeing, where burnout and absenteeism cost businesses billions annually. Technology emerges as a powerful enabler through apps, wearables, and AI systems that can detect early warning signs and deliver personalized support at scale. Eva emphasizes that successful health tech must be co-designed with users and integrated seamlessly into clinical pathways, while better health education is essential to help people interpret their health data meaningfully.

The conversation culminates with Eva's powerful vision for healthcare's future: shifting from short-term thinking to long-term investment that prioritizes prevention over crisis management. "Invest in the future instead of firefighting in the present," she urges, inviting listeners to imagine a society where understanding and maintaining mental wellbeing becomes as routine as brushing our teeth. Connect with Eva on LinkedIn to continue this important conversation about transforming healthcare through prevention.

Do you want to try the quiz from this episode? Find the link on our LinkedIn profile: https://www.linkedin.com/company/labtolives/

Creating virtuous cycles in drug development with Rob Freishtat

Saison 6 · Épisode 7

mercredi 23 avril 2025 • Durée 46:38

Rob Freistat, President of Uncommon Cures, discusses how clinical trials are transforming to accelerate drug development and ensure patients receive treatments faster, particularly in the rare disease space.

• Current market uncertainty and investment challenges in biotech, especially for rare disease research
• Approximately two-thirds of clinical trial processes add no value and aren't required by regulations
• Many clinical trial failures occur not because drugs don't work but because trials can't recruit enough patients
• Companies often treat development phases as "islands" rather than planning for commercial success from the beginning
• Rare disease economics require greater efficiency since development costs must be recovered from much smaller patient populations
• Reviving shelved drug candidates represents a potentially valuable opportunity
• Patients should have greater input in trial design and outcome measures that matter to them
• Better communication between sponsors and regulators could significantly improve drug development

Do you want to try the quiz from this episode? Find the link on our LinkedIn profile: https://www.linkedin.com/company/labtolives/

Would you like to join the show as a guest or collaborator? Find out how on our website: https://www.labtolives.com/

________
Reach out to Ivanna RosendalJoin the conversation on our

Bridging Academia and Biotech: Creating Innovators of Tomorrow with Jonathon Hill

Saison 6 · Épisode 6

mercredi 9 avril 2025 • Durée 33:27

Jonathan Hill takes us on a fascinating journey through the cutting-edge world of DNA sequencing and its revolutionary potential for early disease detection. As both an academic professor at Brigham Young University and co-founder of Wasatch BioLabs, Hill shares how third-generation sequencing technologies are transforming our ability to identify diseases years before symptoms appear.

The conversation centers on a groundbreaking approach using native methylation calling—a method that identifies specific chemical modifications to DNA—to detect neurodegeneration in conditions like Alzheimer's and Parkinson's. Hill explains how these diseases damage the brain for up to a decade before symptoms emerge, creating a critical window where treatment could be most effective. By detecting the unique methylation signatures of dying neurons from cell-free DNA in the bloodstream, Wasatch BioLabs' technology aims to revolutionize diagnosis and treatment monitoring.

What makes this platform particularly powerful is its versatility. The same technology that identifies dying neurons can be adapted to detect signatures from other dying cell types, potentially offering early diagnostics for autoimmune diseases, various cancers, and other conditions—all from a simple blood draw.

Beyond the science, Hill reveals his passion for nurturing the next generation of biotech entrepreneurs. He's created a unique ecosystem at BYU where students with innovative ideas receive the mentorship, lab facilities, and business connections needed to translate academic discoveries into real-world applications. Drawing parallels to the tech boom of Silicon Valley, Hill emphasizes that biotech is experiencing its moment of explosive innovation, though with unique regulatory and infrastructure challenges.

The episode concludes with a thoughtful discussion on regulatory hurdles in life sciences and how streamlining these processes—while maintaining safety standards—could accelerate innovation and save countless lives. For anyone fascinated by the intersection of cutting-edge science, entrepreneurship, and healthcare transformation, this conversation offers an inspiring glimpse into the future of medicine.

Visit

From Lab to Patient: Why Vector Design Makes or Breaks Cell Therapies with Alan Griffith

Saison 6 · Épisode 5

mercredi 26 mars 2025 • Durée 57:47

Vectors are the unsung heroes of cell and gene therapy—molecular couriers that transport therapeutic genes into human cells to treat disease. But as Alan Griffith, Head of Global Operations at Vector Builder reveals, creating these sophisticated delivery vehicles is far more complex than most realize.

Drawing from over a decade of experience developing gene therapies before joining the CDMO sector, Griffith offers rare insight into what makes manufacturing these therapies so challenging. Vector design emerges as the critical yet underappreciated factor determining success or failure. "The fundamental sequence and vector composition itself is so fundamental to manufacturability," Griffith explains, noting how seemingly minor elements can dramatically impact production at scale. This knowledge has evolved painfully over the past decade, with clinical holds and manufacturing failures teaching hard lessons.

The relationship between therapy developers and contract manufacturers proves equally crucial. Rather than transactional exchanges, successful partnerships require deep collaboration and shared risk. "Working with a CDMO is like dancing with someone you don't know," Griffith observes, emphasizing how Vector Builder aims to understand diseases and vector compositions thoroughly rather than simply executing manufacturing orders.

Cost remains perhaps the greatest challenge facing cell and gene therapies. While small molecule drugs might be considered expensive at $10,000 per dose, that figure would be remarkably affordable for gene therapies. Strategies to address this include better vector design to reduce manufacturing failures, more targeted delivery requiring smaller doses, and challenging the "one-and-done" assumption that has proven more complex in reality as expression often diminishes over time.

Looking ahead, Griffith sees complementary roles for both viral vectors and emerging non-viral delivery systems like lipid nanoparticles and exosomes. He predicts viral vectors will continue to dominate certain applications for decades due to their unmatched effectiveness, while non-viral approaches may offer manufacturing advantages and potentially lower costs.

Cell and gene therapies are revolutionary treatments with vectors serving as "molecular couriers" that deliver genetic materials to target cells, but manufacturing these therapies presents significant challenges in scaling, cost, and regulatory compliance.

Tomorrow's Cures Are Hiding in Today's Patient Records with Vish Srivastava

Saison 6 · Épisode 4

mercredi 12 mars 2025 • Durée 25:42

The untapped potential of electronic health records has long been recognized in clinical research, but extracting meaningful insights from this treasure trove of data has remained an elusive challenge—until now.

Vish Srivastava, founder of Century Health, reveals how artificial intelligence is revolutionizing real-world evidence by unlocking critical patient data trapped in EHRs. Traditional patient registries that once took a decade to amass just 1,000 patients can now be created with unprecedented efficiency through AI-powered data extraction. The breakthrough lies in advanced language models that can interpret unstructured clinical notes, transforming them into structured, analyzable data points while maintaining patient privacy.

This technological revolution has profound implications across the drug development lifecycle. In multiple sclerosis research, analyzing 10+ years of longitudinal patient data has illuminated disease progression patterns beyond relapses, informing the next generation of treatments. For approved medications like GLP-1s, real-world evidence is uncovering potential applications in conditions ranging from metabolic disorders to neurodegenerative diseases, potentially fast-tracking label expansions that would traditionally require years of additional clinical trials.

The vision is transformative: reducing the $2.6 billion, 12-year journey of drug development to a fraction of that time while ensuring treatments reach the right patients faster. While Century Health initially focuses on gastroenterology, neurology, and rheumatology in the US market, the underlying technology promises to revolutionize clinical research globally. As Vish notes, "It feels like we can create dramatically better outcomes for patients if we can just make the data that's already collected from their care accessible and actionable."

Do you want to try the quiz from this episode? Find the link on our LinkedIn profile: https://www.linkedin.com/company/labtolives/

Championing Diversity to Transform Clinical Research with Shelli Pavone

Saison 6 · Épisode 3

mercredi 26 février 2025 • Durée 33:31

Join us for a conversation with guest Shelli Pavone, co-founder of Inlightened, to uncover the untapped potential of diversity in clinical trials. Discover how historical mistrust, structural barriers, and exclusion criteria continue to hinder diverse patient recruitment. Shelli sheds light on the transformative impact inclusive trials have on scientific integrity, safety, and the generalizability of results. By embracing diversity, not only do we align with regulatory expectations, but we also pave the way for innovation and trust in our healthcare systems. This episode promises to expand your understanding of why diversity in trial participation is a scientific necessity rather than just a moral obligation.

Explore the importance of diversifying clinical trial staff to boost trial success and enrollment rates. Shelli discusses breaking the mold of traditional investigator homogeneity by incorporating minority physicians, which fosters trust and enhances trial outcomes. Her insights into the creation of Inlightened reveal a passion for revolutionizing access to healthcare expertise, championing diverse voices, and pushing for equitable innovation. Uncover how Enlightened endeavors to challenge the constraints of conventional investment patterns and encourages the industry to embrace ideas that promise greater societal benefits.

This episode covers:

• Exploration of historical mistrust in clinical trials
• Challenges faced in diversifying patient recruitment
• Benefits of having diverse voices in clinical research
• The FDA's evolving stance on diversity in clinical trials
• The role of diverse investigators in influencing patient enrolment
• Strategies to reduce barriers and increase participation
• Shelli's journey and passion for healthcare innovation
• The overarching need for change in the clinical trial landscape

Shelli Pavone: https://www.linkedin.com/in/shelli-pavone-a729b2/

Inlightened: https://getinlightened.com/

Visit

Revolutionizing Neurological Care: Andreas Forsland and Gregg Johns on Assistive Technology and Brain-Computer Interfaces

Saison 6 · Épisode 2

mercredi 12 février 2025 • Durée 57:47

In this episode we dive into Brain-Computer Interface (BCI) technology, where the brain's faint signals are harnessed to create life-changing applications. Andreas Forsland and Greg Johns emphasize the importance of community-driven innovation, guided by the Brainiac Council—a unique assembly of patients, caregivers, and experts. This collaborative approach ensures that the solutions developed address real-world challenges, improving communication and independence for those with severe impairments. The discussion also highlights a groundbreaking clinical trial with the University of Waterloo, showcasing how AI-enhanced devices can reduce social isolation and enhance quality of life.

We also cover:

• Importance of user feedback in product design
• Communication technology for ALS, Parkinson's, and more
• The regulatory challenges of medical device development
• Integrating AI to improve user experience and interaction
• Future vision for accessible health technology
• Ethical considerations surrounding brain-computer interfaces

Guests:
Andreas Forsland: https://www.linkedin.com/in/andreasforsland/
Gregg Johns: https://www.linkedin.com/in/gregg-johns-product-leader/

Do you want to try the quiz from this episode? Find the link on our LinkedIn profile: https://www.linkedin.com/company/labtolives/

Would you like to join the show as a guest or collaborator? Find out how on our website: https://www.labtolives.com/

Revolutionizing Patient Recruitment in Clinical Trials: Unlocking Access and Accelerating Drug Development with Jill Pellegrino

Saison 6 · Épisode 1

mercredi 22 janvier 2025 • Durée 30:32

This episode reveals alarming statistics about patient access to clinical trials, highlighting that only 3% of patients currently have access to participate. Our guest, Jill Pellegrino, CEO of Auto Recruitment, shares innovative strategies to engage the other 90% of the patient population and discusses the importance of digital advertising, pre-screening, and patient support in the recruitment process.

• Discussion on the low percentage of patient access to clinical trials
• Barriers for physicians and research sites in patient enrollment
• Strategies to engage patients through digital advertising
• Importance of pre-screening for trial eligibility
• The role of EMR technology in improving recruitment
• Ensuring patient engagement post-initial interest
• Feedback and response from clinical trial sites
• Future plans for wider patient access to clinical trials
• Emphasis on patient-centric approaches in clinical research

This week, if you have any questions about Auto Recruitment or want to connect with Jill, visit https://www.autorecruitment.com.

Do you want to try the quiz from this episode? Find the link on our LinkedIn profile: https://www.linkedin.com/company/labtolives/

Would you like to join the show as a guest or collaborator? Find out how on our website: https://www.labtolives.com/